Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Mol Cancer Res. 2016 Sep 26;15(1):59–68. doi: 10.1158/1541-7786.MCR-16-0236

Figure 3. AR-V4 and AR-6 dimerize with AR-V7 and AR-FL and also homodimerize.

Figure 3

A. Schematic diagram of the constructs used in the BRET assay. RLuc, RLuc8.6 luciferase; TFP, TurboFP635 fluorescent protein. B & C. Luciferase assay showing AR trans-activating activity in HEK-293T cells co-transfected with the indicated BRET construct and the ARE-luc plasmid. Lower panels, Western blotting confirmation of AR-V expression. D–I. BRET saturation curves showing AR-V4/AR-V7, AR-V6/AR-V7, AR-V4/AR-FL, and AR-V6/AR-FL heterodimerization as well as AR-V4 and AR-V6 homodimerization. Indicated BRET fusion constructs were co-transfected into HEK-293T cells at different ratios. Cells were cultured under androgen-deprived condition unless specified. R1881, 1 nM. *, P < 0.05 from mock control.